AtaiBeckley Inc. (B72)
Summary
B72 Chart
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
The mean of analysts' price targets for AtaiBeckley Inc (ATAI) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
The consensus price target hints at a 33.3% upside potential for AtaiBeckley Inc (ATAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout
LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.
AtaiBeckley Inc. (B72) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AtaiBeckley Inc. ever had a stock split?
AtaiBeckley Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Srinivas G. Rao CEO | XSTU Exchange | US04650F1012 ISIN |
| US Country | 99 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Atai Life Sciences N.V. is a pioneering clinical-stage biopharmaceutical company aimed at revolutionizing the treatment of mental health disorders including depression, anxiety, addiction, and more. Established in 2018, with its roots in Berlin, Germany, and with additional offices in New York and London, Atai Life Sciences is pushing the boundaries of traditional mental health treatment modalities by investing in and developing a wide array of therapeutics. Their mission extends towards addressing the unmet needs in mental health care through a strongly differentiated and diversified portfolio of treatments, embarking on a journey to mitigate the global mental health crisis.
Products and Services
- COMP360 (Psilocybin)
- BPL-003 (Intranasal Formulation)
- TRD
- VLS-01
- ELE-101
- IBX-210
- DMX-1002
- EMP-01
- EGX-A and EGX-B
- RL-007
- GRX-917
- PCN-101 (R-Ketamine)
- KUR-101 (Deuterated Mitragynine)
- RLS-01
A proprietary formulation of psilocybin, currently in a Phase 3 clinical program, focusing on its potential therapeutic effects for mental health disorders.
An innovative intranasal formulation of betahistine in active Phase 2a and 2b clinical studies aimed at treating vertigo with lesser side effects and improved patient outcomes.
A therapeutic under development, details unspecified, targeting treatment-resistant depression.
A transmucosal film in Phase 1b clinical studies targeted at delivering therapeutic agents effectively for mental health conditions.
A serotonergic psychedelic in Phase 1/2a study aimed at treating treatment-resistant depression, showcasing the potential of psychedelics in mental health therapy.
An intravenous formulation of ibogaine under development for treating opioid use disorder, addressing the critical need for effective addiction therapies.
An oral formulation of ibogaine indicated for the treatment of opioid use disorder, exploring a different administration route for ibogaine's therapeutic effects.
An oral formulation of an R-MDMA derivative being developed for post-traumatic stress disorder, expanding the therapeutic options for PTSD.
Psychotropic substances with novel, non-tryptamine structures offering differentiated 5-HT receptor pharmacology, aiming at unique mental health treatment pathways.
An orally bioavailable compound acting as a pro-cognitive neuromodulator, under investigation for the cognitive impairment associated with schizophrenia.
A deuterated version of etifoxine designed for the treatment of generalized anxiety disorder, highlighting an approach to minimize anxiety with potentially reduced side effects.
A subcutaneous formulation of R-ketamine focused on psychiatric indications initially targeting treatment-resistant depression, demonstrating the therapeutic versatility of ketamine.
A formulation of deuterated mitragynine under development for the treatment of opioid use disorder, reflecting on the need for innovative addiction treatments.
Indicated for treatment-resistant depression, RLS-01 represents Atai's dedication to finding solutions for those who haven't responded to existing treatments.
